Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.

Original publication

DOI

10.3899/jrheum.170150

Type

Journal article

Journal

J rheumatol

Publication Date

05/2017

Volume

44

Pages

697 - 700

Keywords

GRAPPA, OMERACT, OUTCOME MEASURES, PSORIASIS, PSORIATIC ARTHRITIS, Antirheumatic Agents, Arthritis, Psoriatic, Humans, Outcome Assessment (Health Care), Rheumatology, Treatment Outcome